share_log

Loss-Making LifeMD, Inc. (NASDAQ:LFMD) Expected To Breakeven In The Medium-Term

Loss-Making LifeMD, Inc. (NASDAQ:LFMD) Expected To Breakeven In The Medium-Term

亏损的LifeMD公司(纳斯达克股票代码:LFMD)预计在中期内实现盈亏平衡。
Simply Wall St ·  06/24 06:37

With the business potentially at an important milestone, we thought we'd take a closer look at LifeMD, Inc.'s (NASDAQ:LFMD) future prospects. LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company's loss has recently broadened since it announced a US$24m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$26m, moving it further away from breakeven. Many investors are wondering about the rate at which LifeMD will turn a profit, with the big question being "when will the company breakeven?" In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

鉴于业务有可能达到一个重要的里程碑,我们想仔细研究一下LifeMD, Inc.(纳斯达克:LFMD)的未来前景。LifeMD, Inc.作为一家直接面向患者的远程医疗公司,在美国连接患者和医疗专业人士开展医疗保健业务。自全财年宣布US$24m亏损以来,该公司的亏损最近已经扩大,达到了US$26m的最新滚动十二个月亏损,距离盈亏平衡进一步远离。许多投资者都在想知道LifeMD将何时实现盈利平衡,大问题是“公司何时才能实现盈亏平衡?”在本文中,我们将涉及对公司增长预期和分析师预计何时盈利的一些讨论。

Consensus from 6 of the American Healthcare Services analysts is that LifeMD is on the verge of breakeven. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$3.8m in 2025. So, the company is predicted to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 126% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

美国医疗服务业的六名分析师普遍认为,LifeMD已经接近盈亏平衡点。他们预计该公司将在2024年承担最终亏损,并在2025年创造出US$3.8m的正利润。因此,该公司预计将在仅在一年多的时间内达到盈亏平衡点。公司每年需要以多快的速度增长才能在2025年达到盈亏平衡点?从分析师的预测来看,他们预计公司平均每年增长126%,这是相当乐观的!如果这种速度被证明过于激进,公司可能会比分析师预测的时间更晚地实现盈利。

earnings-per-share-growth
NasdaqGM:LFMD Earnings Per Share Growth June 24th 2024
纳斯达克GM:LFMD每股收益增长至2024年6月24日。

Given this is a high-level overview, we won't go into details of LifeMD's upcoming projects, however, take into account that typically healthcare tech companies, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

鉴于这只是一个高层次的概述,我们不会详细说明LifeMD的即将到来的项目,但需要注意的是,根据产品开发的阶段,医疗技术公司会有不规律的现金流周期。这意味着,高增长率并不罕见,特别是如果该公司目前处于投资期。

One thing we would like to bring into light with LifeMD is its debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn't exceed 40% of your equity, which in this case, the company has significantly overshot. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.

我们想要揭示的LifeMD的一件事是其超过2倍的负债股本比率。一般来说,负债不应超过股本的40%,而在这种情况下,该公司已经明显超标。更高的债务水平需要更严格的资本管理,这增加了投资这家亏损公司的风险。

Next Steps:

下一步:

There are key fundamentals of LifeMD which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at LifeMD, take a look at LifeMD's company page on Simply Wall St. We've also compiled a list of essential aspects you should look at:

本文中未涵盖到的LifeMD的关键基本面,其中我们必须再次强调,这仅仅是一个基本概述。如果您要更全面地了解LifeMD,请访问Simply Wall St上LifeMD的公司页面。我们还编制了一份必要的要素列表:

  1. Valuation: What is LifeMD worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether LifeMD is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on LifeMD's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
  1. 估值:LifeMD今天的价值是多少?未来的增长潜力已经反映在价格中了吗?我们免费的研究报告中的内在价值信息图有助于可视化LifeMD目前是否被市场错误定价。
  2. 管理团队:一支经验丰富的管理团队可以增加我们对业务的信心-请查看LifeMD董事会和CEO的背景。
  3. 其他高表现的股票:是否有其他表现更好的股票并具有经过验证的历史记录?查看这里的免费列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发